Last checked at (Sharecast News) - The Covid-19 vaccine candidate being developed by Pfizer and BioNTech has shown an elevated degree of efficacy in preventing Covid-19 among those aged 65 and over.
Fresh data from the companies' ongoing late-stage clinical trial revealed a greater than 94% efficacy in preventing the onset of the illness provoked by the novel coronavirus among older adults, according to reports.
The latest findings are derived from the ongoing late-stage clinical study, which involves 41,000 people from around the world who were given two doses of the experimental vaccine.
Interim efficacy data published on 9 November had shown a greater than 90% efficacy among all trial participants, with the companies having demured from providing a precise reading as the results could vary as the trial progressed.
Overall, Monday's figures showed that efficacy across all age groups was 95%.
Of the 170 trial participants who had contracted Covid-19 thus far, 162 had been given placebo.
Nine severe cases of Covid-19 were registered, only one of which was among the volunteers who had received the vaccine.
8 May 2024 19:10
Sector movers: Aerospace and Defence, Pharma pace gains
(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.
Read more
